Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
ID: 359143Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359143

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-25-012.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Rational Design of Vaccines Against Hepatitis C Virus (HCV), inviting applications for cooperative agreements to establish Research Centers focused on vaccine development. The initiative aims to advance HCV vaccine candidates through design, optimization, and evaluation, emphasizing the structural and immunological foundations for broad protection against the virus, while leveraging existing human cohorts and animal models for evaluation. NIH plans to allocate $8.3 million in FY 2026 for 2-4 awards, with each project having a maximum budget of $2 million per year and a project period of up to five years; applications are due by November 7, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-25-012-Full-Announcement.html
    RFA-AI-25-012.html
    The Department of Health and Human Services (HHS) and the National Institute of Allergy and Infectious Diseases (NIAID) have issued a Notice of Funding Opportunity (NOFO) (RFA-AI-25-012) to establish Research Centers for the rational design and development of vaccines against Hepatitis C Virus (HCV). This initiative seeks applications for cooperative agreements to advance HCV vaccine candidates towards clinical evaluation by focusing on design, optimization, and evaluation. The NOFO emphasizes understanding the structural and immunological basis for broad protection against HCV, leveraging existing human cohorts, and evaluating vaccine strategies in animal models. Clinical trials are not permitted. NIAID plans to commit $8.3 million in FY 2026 for 2-4 awards, with a maximum project period of five years and budgets not exceeding $2 million in direct costs per year. Eligible applicants include various institutions, though foreign subawards/subcontracts are not allowed. Applications must include an Administrative Core and at least two Research Projects, with optional Scientific Cores. Substantial NIH involvement is anticipated post-award.
    Similar Opportunities
    HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "HIV Vaccine Research and Design (HIVRAD) Program," aimed at advancing research for an effective prophylactic vaccine against HIV/AIDS. This grant encourages multi-disciplinary projects that address significant scientific questions in vaccine discovery, including preclinical evaluations in non-human primate models, while explicitly prohibiting clinical trials. The NIH plans to fund 1-2 awards totaling approximately $5 million for fiscal year 2025, with applications due by March 13, 2024, and an open submission date starting February 13, 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application guidelines available at https://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html.
    Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV) program, aimed at advancing research in the field of infectious diseases. This initiative seeks to support innovative research that elucidates mechanisms of persistence and pathogenesis of Hepatitis B, develops clinically relevant biomarkers, identifies new drug targets, and creates non-invasive diagnostics, leveraging existing clinical data and sample repositories. With an estimated total program funding of $8 million and the expectation of awarding two grants, interested small businesses should note that the application process is open, with key deadlines including an estimated synopsis close date of August 19, 2026, and an anticipated award date of March 1, 2027. For further inquiries, applicants can contact Josh Radke, Ph.D., at josh.radke@nih.gov or by phone at 301-761-6525.
    Coccidioidomycosis Collaborative Research Centers
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Coccidioidomycosis Collaborative Research Centers" aimed at advancing research to develop a vaccine for coccidioidomycosis, commonly known as Valley fever. This initiative seeks to support multi-disciplinary research centers that will address critical gaps in basic research, develop necessary tools and resources, and ultimately create a preventative vaccine for this serious fungal infection endemic to various regions in the United States. The grant is open to a wide range of eligible applicants, including Indian/Native American Tribal Governments, federal agencies, community-based organizations, and foreign institutions, with no cost-sharing or matching requirement. Interested parties can reach out to Dr. Dona Love at dona.love@nih.gov or by phone at 301-761-7788 for further information. The estimated synopsis post date is January 5, 2026, with a closing date for applications on March 6, 2026, and an anticipated award date of December 1, 2026.
    Consortia for Structure-based Immunogen Design for HIV (CSID-HIV)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Consortia for Structure-based Immunogen Design for HIV (CSID-HIV)" aimed at advancing research in the design of HIV immunogens that can induce broadly neutralizing antibody (bNAb) responses. This initiative seeks to support coordinated multidisciplinary efforts to overcome critical challenges in immunogen design, ultimately facilitating the development of safe and effective HIV therapeutics and vaccines. The funding will be provided through a cooperative agreement, with no cost-sharing or matching requirements, and is open to a diverse range of eligible applicants, including tribal governments, federal agencies, and community-based organizations. Interested parties should contact Dr. Stuart Z. Shapiro at sshapiro@niaid.nih.gov or call 240-292-6155 for further information. The estimated project start date is January 1, 2027, with a synopsis close date of April 14, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) aimed at addressing vaccine hesitancy, uptake, and implementation among populations experiencing health disparities. This initiative seeks to promote community-engaged research through a Notice of Special Interest (NOSI) specifically for R01 projects, highlighting the critical need for targeted research in this area. The FOA is expected to be published in December 2020, with applications accepted in February 2021 for fiscal year 2021 funding, and awards anticipated by September 2021. For further inquiries, interested applicants can contact Deborah E. Linares, Ph.D., at deborah.linares@nih.gov or by phone at 301-402-2516.
    Pilot Projects to Enhance the Human Virome Program (R03, Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for pilot projects aimed at enhancing the Human Virome Program through a grant titled "Pilot Projects to Enhance the Human Virome Program (R03, Clinical Trials Not Allowed)." This initiative seeks to support small businesses in developing innovative projects that advance the understanding of the healthy human virome, including its characterization, tools, and interactions with the host, while ensuring that proposed projects do not overlap with existing efforts. With an estimated total program funding of $2,000,000 and the expectation of awarding six grants, interested applicants are encouraged to prepare their proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release, which is expected to be published on September 15, 2025. For further inquiries, potential applicants can contact Amanda Melillo, PhD, at amanda.melillo@nih.gov or by phone at 301-529-7217.
    Centers for AIDS Research (CFAR)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Centers for AIDS Research (CFAR)" aimed at advancing HIV/AIDS research through the establishment and support of a national network of CFARs. This initiative seeks to foster multidisciplinary collaborations and provide infrastructure that enhances the efficiency and effectiveness of HIV/AIDS research, particularly by supporting early-career investigators and funding innovative pilot studies. With an estimated total program funding of $4,202,000 and an expected six awards, interested applicants, including various organizations and non-domestic entities, should note that the application period is open until August 19, 2026, with awards anticipated to be made by March 1, 2027. For further inquiries, applicants can contact the CFAR Program at CFARprogram@mail.nih.gov or call 240-459-2852.
    Notice of Intent to Publish a Funding Opportunity Announcement for Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the continuation of the NIDDK Hematology Central Coordinating Center (HCC) under a cooperative agreement. The HCC will collaborate with up to five Cooperative Centers of Excellence in Hematology (CCEH) to provide administrative support, develop communication strategies, and implement educational programs aimed at enhancing research in nonmalignant hematology. This initiative is crucial for fostering a national multidisciplinary research effort to study hematopoiesis and address nonmalignant hematologic diseases. The estimated total program funding is $1 million, with a single award anticipated, and the NOFO is expected to be published in December 2024, with applications due by March 2025. For further details, potential applicants should prepare to submit their proposals in alignment with the requirements outlined in the forthcoming NOFO.
    Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis (R01 Clinical Trial Not Allowed)." This initiative aims to solicit research applications focused on the preclinical development of lead candidate vaccines to combat Mycobacterium tuberculosis (Mtb) infection and disease, thereby enhancing the clinical pipeline of viable vaccine candidates. The program is critical for advancing public health efforts against tuberculosis, a significant global health challenge. The estimated total funding for this program is $4,730,000, with approximately five awards expected. Interested applicants can reach out to Katrin Eichelberg, MSc, PhD, at keichelberg@nih.gov or call 240-669-2921 for further information. Key deadlines include an estimated synopsis post date of September 8, 2025, and a close date of November 7, 2025, with awards anticipated to be made by July 1, 2026.
    Implementation Science to End the HIV Epidemic
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Implementation Science to End the HIV Epidemic," aimed at advancing efforts to combat HIV through innovative research-community collaborations. The initiative seeks projects that will develop and evaluate strategies for HIV prevention, diagnosis, treatment, and outbreak response, particularly in communities disproportionately affected by the epidemic. This funding, totaling an estimated $7 million, will support approximately 10 awards, with applications open to a diverse range of eligible entities, including tribal governments, federal agencies, and community-based organizations. Interested applicants should note that the estimated synopsis close date is April 17, 2026, and the anticipated award date is December 1, 2026; for further inquiries, contact Rebecca Mandt, Ph.D., at rebecca.mandt@nih.gov or call 301-435-7695.